-
These drugs recently received final approval from the U.S. Food and Drug Administration (FDA).
-
This second part of the palonosetron formulary evaluation addresses the available clinical trial, adverse effects, and cost analysis data.
-
-
Fertility programs worldwide need to change their methods for calculating successful birth rates to emphasize births of single babies at term as the desired outcome of assisted reproductive technologies, rather than the birth of twins or triplets, an Australian researcher argues.
-
A woman seeking help conceiving through assisted reproduction inquires about the possibility of using her sister as an egg donor because previous attempts using her own have failed. Would your program allow it?
-
Stung by criticism that it is not doing enough to enforce its own regulations governing direct-to-consumer advertising by pharmaceutical companies and medical device manufacturers, the U.S. Food and Drug Administration (FDA) announced the publication of three new guidance documents designed to improve communications the public sees about new drugs and devices.
-
Aetnas award-winning disease management programs focus the companys resources and nursing skills on the patients for whom it can make the biggest difference.
-
Even if your hospital was not named in the recent wave of lawsuits against charitable providers, the alarm bell is ringing and you need take action now.
-
When it comes to EMTALA, you dont want to just toe the line, says Bryan Liang, PhD, a professor of law, medicine, and public policy at California Western School of Law in San Diego. You want to be so far away from the line that no one could even suggest you crossed it.
-
Kim YH. Mindulness meditation and chronic pain. Altern Med Alert 2004;7(3):33-35.
